Abiogen

Abiogen Pharma is a private, commercial-stage Italian pharmaceutical company with a century-long family legacy condensed into its modern corporate structure. It has a diversified portfolio targeting bone metabolism, hypovitaminosis D, pain, viscosupplementation, dermatology, respiratory, and diabetology. The company is revenue-generating, reported a €168 million turnover in 2024, employs approximately 460 people, and exports to over 40 countries, demonstrating a solid commercial footprint in Italy and internationally. Its strategy includes growth through acquisitions, such as the 2023 purchase of Effrx, and is under the management and coordination of MDM Holding S.p.A.

Integrated commercial platform for small molecule pharmaceuticals, food supplements, medical devices, and medical foods across established therapeutic areas.

Operates in highly competitive, established markets dominated by global pharmaceutical giants and generic manufacturers. Competes on brand reputation, physician relationships, and portfolio breadth within specific therapeutic niches rather than on novel technology. Also competes with other mid-size European pharma companies and consumer health firms in the supplement and medical device spaces.